Company: Cipla Ltd. Category: Result Analysis

At CMP, stock trades at PE multiples of 21.6x and 18.3x of FY19E and FY20E EPS, respectively, which appear to be expensive. Rolling over our estimates to FY20E, we maintain our HOLD recommendation on the stock with a revised Target Price of Rs675 (from Rs620 earlier).
Feb. 9, 2018, 12:50 p.m.

Cipla: 3QFY18 Result Update
Feb. 8, 2018, 10:09 a.m.
Author : Nirmal Bang | Publisher:

Cipla: 2QFY18 Result Update
Nov. 9, 2017, 10:49 a.m.

Shares of Cipla jumped as much as 4.6% in Wednesday's trade as the company reported a consolidated net profit of Rs. 434.95 crore for the second quarter ended September, 3017 against Rs. 369.64 crore in the corresponding period of the previous fiscal, beating market expectations.
Nov. 8, 2017, 11:39 a.m.

Cipla: 2QFY18 Result Update
Nov. 8, 2017, 10:57 a.m.
Author : Nirmal Bang | Publisher:

Pharma firm Cipla on Tuesday reported 19.26 per cent year-on-year rise in consolidated profit at Rs 422.59 crore for the quarter ended September 30 against Rs 354.34 crore in the corresponding quarter last year. ET Now poll had predicted a consolidated profit of Rs 424 crore in Q2FY18.
Nov. 7, 2017, 4:46 p.m.

Cipla reported Q1FY18 Sales, adj. EBITDA and adj. PAT of Rs34.3bn, Rs5.5bn and Rs3.3bn (excluding one‐off other income of Rs1.18bn) Vs our estimates of Rs37.7bn, Rs6.1bn and Rs3.7bn. Post adjustments for one‐off sales and one‐off GST impact of Rs450m, adj. EBITDA margin was 16.4% in Q1FY18 due to better control on opex and synergies from Invagen acquisition, as claimed by the management
Oct. 4, 2017, 5:33 p.m.

Cipla: Result Update - Nirmal Bang
Aug. 24, 2017, 12:12 p.m.
Author : Nirmal Bang | Publisher:

Cipla: Result Update - Angel Broking
Aug. 23, 2017, 2:29 p.m.

Q1FY18 revenue declined 3% YoY to INR35.3b (~15% miss). Gross margin came in at 65.7% (+ >400bp YoY; +340bp QoQ). Current quarter gross margin includes ~150bp of one-off benefit, which is not expected to get repeated in the coming quarters. Neutral.
Aug. 22, 2017, 4:50 p.m.